CCXI Stock: ChemoCentryx, Inc. Stock Price, Analysis & Insights
Get live ccxi stock price $51.99, comprehensive ChemoCentryx, Inc. stock analysis, charts, news, and expert forecast. Real-time ccxi stock data and investment insights.
Company Overview
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
Company Information
- CEO
- Thomas Schall
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 178
Contact Information
- Website
- https://www.chemocentryx.com
- Address
- 850 Maude Ave
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 0 market capitalization
- Trading Volume: 656.22K shares traded today
- Price Range: 52-week range of $14.95 - $52.00
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for ChemoCentryx, Inc.
ChemoCentryx, Inc. (CCXI) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 0, the company represents a significant player in its market. The stock is currently trading at $51.99 with a positivedaily change of 0.00%.
The company's 178 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -25.93, beta of 1.23, and 52-week price range from $14.95 to $52.00when evaluating investment opportunities.
Why Invest in ChemoCentryx, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Thomas Schall
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.